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 Respiratory depression is a serious and potentially lethal adverse effect of opioid medications 
that must be considered to achieve safe opioid pain management in clinical practice. The patient 
demographics; age, sex, height, weight, body mass index, smoking status, race, amount of opioid 
received in the operating room, amount of opioid received in the post anesthesia care unit 
(PACU), sedation score postoperatively, American Society of Anesthesiologists (ASA) Physical 
Status, and genetic variants from identified candidate genes; OPRM1, ABCB1, COMT, and 
CYP2D6 were potential risk factors that were analyzed for association with opioid induced 
respiratory depression after surgery for orthopedic trauma.  
A sample of 152 subjects aged 18-70 that received surgeries for orthopedic trauma were 
included in this study. Subject characteristics data were collected from both subject reports and 
medical records. Data regarding respiratory rate postoperatively was collected in the post 
anesthesia care unit at 15 and 45 minutes postoperatively. DNA extraction was performed with 
saliva samples from the subjects. Sequencing was performed using Big Dye Cycle Sequencing 
reagents to determine OPRM1 genotype. Taqman allele discrimination was used to genotype 
ABCB1, COMT, and CYP2D6 genes.  
The patient characteristics ASA physical status and sedation score were associated with 
differences in respiratory rate at 15 and 45 minutes postoperatively. Differences in subject 
genotype on the ABCB1 gene single nucleotide polymorphism (SNP) (rs1045642) were 
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associated with differences in respiratory rate 45 minutes postoperatively. CYP2D6 metabolizer 
group differences were associated with difference in respiratory rate at 15 minutes 
postoperatively.  
This study provided evidence in support of the use of ASA Physical Status, sedation 
score, ABCB1 SNP (rs1045642), and CYP2D6 metabolizer groups to identify individuals at 
increased risk for opioid induced respiratory depression postoperatively. 
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1.0  CHAPTER 1: INTRODUCTION 
Effective pain management is crucial to safe and effective patient care. A sentinel event alert was 
issued by the Joint Commission in August 2012 that emphasized the importance of safe pain 
management with opioids, as many adverse events have been linked with the use of opioid 
medications (The Joint Commission, 2009). Respiratory depression is a serious and potentially 
lethal adverse effect of opioid administration that must be considered to achieve safe opioid pain 
management in clinical practice. 
Data collected from 152 adult patients that received surgery for orthopedic trauma were 
used for analysis of respiratory depression with associated risk factors. Orthopedic trauma 
patients receiving surgery are an optimal patient population for studying pain management, as 
orthopedic surgical procedures are rated as being moderate to severely painful (Sinatra, Torres, 
& Bustos, 2002). Potential risk factors for opioid induced respiratory depression that were 
analyzed included age, sex, height, weight, body mass index, smoking status, race, amount of 
opioid received in the operating room, amount of opioid received in the post anesthesia care unit 
(PACU), sedation score postoperatively, American Society of Anesthesiologists (ASA) Physical 
Status, and genotype data including: CYP2D6 metabolizer group, and single nucleotide 
polymorphism (SNPs) from the candidate genes of interest OPRM1, COMT, and ABCB1. This 
study sought to answer the question; what are the risk factors for respiratory depression in 
orthopedic trauma patients receiving opioids for pain management postoperatively? 
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Identification of risk factors for opioid induced respiratory depression will allow healthcare 
providers to manage delivery, develop monitoring strategies, and increase vigilance in the 
delivery of opioids in patients with known risks. An awareness of an individual patient’s risk 
factors for opioid induced respiratory depression will improve patient safety with the use of 
opioids. 
A sample of 152 adult subjects that received surgery for orthopedic trauma was recruited 
from Presbyterian Hospital of UPMC. Age, sex, height, weight, body mass index, smoking 
status, race, amount of opioid received in the operating room, amount of opioid received in the 
post anesthesia care unit (PACU), sedation score postoperatively, and American Society of 
Anesthesiologists (ASA) Physical Status, were determined by patient report or from information 
retrieved from the medical record. Saliva samples were collected from consented and enrolled 
subjects for DNA extraction. Genotyping for COMT, ABCB1, and CYP2D6 SNPs was 
determined through the use of Taqman Allelic Discrimination Assays (Applied Biosystems, 
Foster City, CA). Genotypes for OPRM1 SNPs were identified through the use of Big Dye Cycle 
Sequencing reagents (Applied Biosystems, Foster City, CA).  
The subject characteristics that were found to have a significant effect on respiratory rate 
postoperatively at both 15 and 45 minutes were American Society of Anesthesiologists (ASA) 
Physical Status, sedation score at 15 minutes postoperatively and sedation score at 45 minutes 
postoperatively. CYP2D6 metabolizer group classification was found to be significantly 
associated with respiratory rate at 15 minutes postoperatively. The ABCB1 SNP (rs1045642) was 
found to be significantly associated with respiratory rate at 45 minutes postoperatively. These 
results support the use of ASA physical status, sedation score at 15 minutes and 45 minutes, 
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CYP2D6 metabolizer group, and ABCB1 SNP (rs1045642) in the identification of individuals at 
risk for postoperative opioid induced respiratory depression.  
1.1 PURPOSE 
Currently there is limited evidence to determine risk factors for opioid induced respiratory 
depression (Jarzyna et al., 2011; Stoelting & Weinger, 2009). Further evidence regarding 
identification of risk factors for opioid induced respiratory depression will provide guidance for 
development of clinical interventions and protocols aimed at increasing vigilance in patients at 
heightened risk for adverse outcomes. Understanding of the etiology and mechanisms of opioid 
induced respiratory depression can lead to the development of targeted interventions based on 
identification of risk factors including genetic variants identified on candidate genes. 
Identification of risk factors could be clinically useful for all surgical patients. Postoperative 
patients observed for limited periods of time, particularly those that are ambulatory surgery 
patients or outpatients, as well as the inpatient population in the hospital setting will benefit from 
pain management strategies targeted to decrease the occurrence of opioid induced respiratory 
depression secondary to opioids.  
Effective pain management is considered a patient right during treatment. Pain has been 
recognized as the “fifth vital sign” by the American Pain Society (American Pain Society, 2008) 
to encourage frequent and thorough assessment by healthcare providers. Adequate pain control is 
crucial because healthcare providers aim to minimize patient suffering as well as the negative 
consequences that unrelieved pain has on the body. Unrelieved pain is known to cause other 
negative consequences on physiology, development, psychology, future pain and quality of life 
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(Pasero & McCaffery, 2011).  Adequate pain control can aid in avoiding these negative effects, 
making pain management central to achieving the best possible patient outcomes.  
In the hospital setting opioids are the most common type of pain medication administered 
for pain. Respiratory depression is a dangerous adverse effect of opioid use that must be 
considered to achieve safe opioid pain management. Nurses play a central role in pain 
management as well as in the identification and treatment of respiratory depression. Exploration 
of risk factors for opioid induced respiratory depression will aid in safe and effective 
management of pain. Fear of opioid induced respiratory depression and other adverse effects can 
lead to under treatment of pain. Conversely, if excess opioid is administered, respiratory 
depression, a potentially fatal adverse effect may occur. Exploring this topic to achieve a better 
understanding of opioid induced respiratory depression will enable healthcare providers to treat 
pain safely and effectively. 
Variability of patients’ experience of pain, can make treatment of pain challenging. 
Patient report of pain has been found to be the most effective means available for pain 
measurement.  “Pain is whatever the experiencing person says it is, existing whenever he/she 
says it does” (McCaffery, 1968). This is the gold standard definition of pain used in clinical 
practice. Efficacy of pain medication given is also measured by patient report of pain score 
during pain reassessment. Identification of significant risk factors for opioid induced respiratory 
depression can aid in the clinical management of patients receiving opioids for pain 
management. Establishment of risk factors for opioid induced respiratory depression will 
contribute significantly to healthcare professionals’ goal of achieving safe and adequate pain 
management. 
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Data collected from 152 adult patients that received surgery for orthopedic trauma will be 
used for analysis of respiratory depression with associated risk factors. Potential risk factors will 
include age, sex, height, weight, body mass index, smoking status, race, amount of opioid 
received in the operating room, amount of opioid received in the PACU, sedation score 
postoperatively, American Society of Anesthesiologists (ASA) Physical Status and genotypes. 
Specific genetic variants will be evaluated in candidate genes of interest including: OPRM1, 
COMT, ABCB1, and CYP2D6. Orthopedic trauma patients undergoing surgery are an optimal 
patient population for studying pain management, due to the severe pain associated with 
orthopedic trauma and history of under treatment of pain in this patient population (Sinatra et al., 
2002). Analysis of these data will seek to answer the question; what are the risk factors for 
respiratory depression in orthopedic trauma patients receiving opioids for pain management 
postoperatively? 
1.2 SPECIFIC AIMS 
Patient factors were evaluated for potential associated risk for opioid induced respiratory 
depression in 152 adult patients that received surgery for orthopedic trauma.  Both demographic 
and clinical factors including age, gender, height, weight, body mass index, smoking status, race, 
sedation score postoperatively, amount of opioid received in the operating room, amount of 
opioid received in the PACU, ASA Physical Status and genetic risk factors including genetic 
variants on candidate genes, specifically OPRM1, ABCB1, COMT, and CYP2D6 were evaluated 
for risk of opioid induced respiratory depression. The purpose of this study was to identify those 
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subject risk factors that contributed to risk of opioid induced respiratory depression 
postoperatively. 
Aim 1. Explore the patient demographics; age, sex, height, weight, body mass index, 
smoking status, race, sedation score postoperatively, amount of opioid received in the operating 
room, amount of opioid received in the PACU and ASA Physical Status for presence of a 
significant relationship in the development of opioid induced respiratory depression after surgery 
for orthopedic trauma. 
Aim 2. Explore genetic variants for identified candidate genes; OPRM1, ABCB1, COMT, 
and CYP2D6 to determine if specific genotypes contribute to increased risk for opioid induced 
respiratory depression after surgery for orthopedic trauma. 
Identification of risk factors including genetic variants for opioid induced respiratory 
depression will aid in the individual management of respiratory depression in the context of 
opioid pain treatment. 
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2.0  CHAPTER 2: LITERATURE REVIEW 
2.1 ASSESMENT OF PAIN 
The International Association for the Study of Pain defines pain as  “ An unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described in terms of 
such damage” (International Association for the Study of Pain, 1994). Although pain is an 
intense sensation for affected individuals, variation exists in the way pain is experienced and 
expressed. Pain does not always have obvious direct physical manifestations or physiologic 
indications, necessitating that healthcare providers assess pain. Patient report is the most accurate 
method of pain assessment.  “Pain is whatever the experiencing person says it is, existing 
whenever he/she says it does” (McCaffery, 1968). Treatment is initiated in response to pain 
assessment, followed by reassessment to evaluate effectiveness of this treatment. In recent years 
assessment of pain has been emphasized and healthcare providers have been encouraged to 
aggressively treat pain (American Pain Society, 2008). As part of the movement to closely 
monitor pain in the hospital setting, pain has been referred to as the fifth vital sign by the 
American Pain Society (American Pain Society, 2008), encouraging assessment of pain as 
frequently as other vital signs (American Pain Society, 2008). Regular assessment of pain by the 
health care provider is essential because many patients will not spontaneously express pain 
(American Pain Society, 2008). 
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In order to accurately assess pain, the appropriate pain scale according to the 
developmental level and communication abilities of the patient must be used. Currently, the most 
widely used pain scale is the 0-10 scale (Krebs, Carey, & Weinberger, 2007). When using the 0-
10 scale to assess pain, the patient is asked to assign their current pain a number rating on a scale 
from 0-10, 0 being no pain and 10 being the worst pain imaginable. Treatment decisions are 
made based on patient reported pain level. The way that each individual rates their pain may 
differ depending on pain tolerance and pain perception. Certain patients may be more prone to 
subscribing higher or lower ratings to their pain depending on perception of their pain. 
Regardless of this individual variation in pain rating healthcare providers should take patient 
reported ratings as the truth. Comparison of pain ratings and looking at trends of pain scores over 
time is a useful way to evaluate the effectiveness of the patient’s pain treatment (Pasero & 
McCaffery, 2011). 
2.2 HISTORICAL METHODS OF OPIOID PAIN TREATMENT 
Opium, the latex derived from the opium poppy flower, was originally used for recreational 
purposes in ancient times (Hamilton & Baskett, 2000). The application of opioids to 
postoperative pain management was first noted in the 1700s (Hamilton & Baskett, 2000). 
Although incapable of providing surgical anesthesia, it was found that oral opioids were a quality 
means of postoperative pain relief. The first published report of the systemic effect of morphine 
was by Charles Hunter in the Medical Times Gazette in 1858 (Hamilton & Baskett, 2000). Prior 
to this it was thought that morphine exerted mostly local pain control effects. 
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2.3 OPIOID PAIN MANAGEMENT 
Endogenous opioids are naturally occurring peptides in the body that are thought to play a role in 
opioid analgesia. The precise physiologic purpose of endogenous opioids is unknown, but it is 
known that opioid medications produce their effects by imitating endogenous opioids (Pasero & 
McCaffery, 2011). Opioid receptors are the sites where endogenous opioids and opioid 
medications bind and the mechanisms for exerting pain relieving effects (Pasero & McCaffery, 
2011). 
Detrimental effects on physiology, development, psychology, future pain and quality of 
life have been noted as a result of untreated pain (Pasero & McCaffery, 2011). Undertreated 
postoperative pain can lead to decreased immune function due to activation of hypothalamus-
pituitary-adrenal hormonal changes (Hutchison, 2007; Pasero & McCaffery, 2011). Increased 
sympathetic nervous system activation secondary to untreated pain may have negative effects on 
the cardiac, gastrointestinal, and renal systems (Hutchison, 2007; Pasero & McCaffery, 2011).  
These negative systemic effects of untreated pain can cause impaired or delayed healing, leading 
to poor patient outcomes (Hutchison, 2007; Pasero & McCaffery, 2011).  
One of the barriers to effective pain treatment is the presence of breakthrough pain, 
additional pain despite treatment. This pain may be brought on by engaging in an activity that 
causes additional pain or the onset of pain towards the end of the dose of pain medication. The 
presence of breakthrough pain indicates the need for changes in pain treatment. Once a patient 
starts to experience breakthrough pain it can be difficult to regain control of pain. In efforts to 
prevent breakthrough pain patients may be placed on continuous scheduled opioid doses to 
ensure that the patient stays pain free.  The goal of pain treatment is to keep the patient pain free 
and prevent the occurrence of breakthrough pain. 
 9 
Over time as the uses of opioids were explored and different forms of opioids were 
developed, public misconceptions were also formed. A prevalent misconception about opioids is 
that taking opioids for pain relief causes addiction (Pasero & McCaffery, 2011). This fear of 
opioid addiction may be held by the patient, the healthcare provider or both, and creates a 
significant barrier to effective pain management (The Joint Commission, 2012). Taking opioids 
for pain relief purposes results in addiction at a rate of less than 1 percent (Pasero & McCaffery, 
2011). 
2.4 RESPIRATORY FUNCTION 
The respiratory system requires the orchestration of many body systems in order to properly 
function. The pulmonary system and the central nervous system (CNS) function in conjunction 
with one another to achieve effective respiration (Levitzky, 2013). The lungs, a critical organ in 
respiratory system, perform breathing, the inhalation and exhalation of air, and gas exchange, 
taking oxygen from the air and transporting it into the bloodstream, and removing carbon dioxide 
from the body and expelling it into the air (Weinberger, Cockrill, & Mandel, 2008).  The impulse 
and drive to breathe is created by muscles of the chest wall and diaphragm (Weinberger et al., 
2008). The contraction of these muscles is triggered by signals transmitted by the CNS from 
neurons in the medulla through the spinal cords to the nerves that innervate the respiratory 
muscles (Levitzky, 2013). 
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2.5 OPIOID INDUCED REPIRATORY DEPRESSION 
The depression or reduction in respiratory functioning is a dangerous adverse effect of opioids 
that can be potentially fatal (Yaksh & Wallace, 2011). Opioids affect the relationship between 
the respiratory and neurologic systems to create a depressant effect. Drive for rhythm of 
respirations is decreased by the effect of opioid on mu opioid receptors and delta opioid 
receptors (Yaksh & Wallace, 2011). This is manifested by a decreased respiratory rate and 
altered respiratory pattern (Yaksh & Wallace, 2011). Opioids also alter respiratory function by 
diminishing the respiratory response to increased carbon dioxide and decreased oxygen (Yaksh 
& Wallace, 2011). The excitability of chemoreceptors that normally facilitate communication of 
the presence of high carbon dioxide or low oxygen is lessened by the presence of opioids (Yaksh 
& Wallace, 2011). The presence of high amounts of carbon dioxide or low amounts of oxygen 
can have detrimental effects on the body in the regulation of acid-base balance (Levitzky, 2013). 
The situation in which a patient is experiencing respiratory depression this acid-base balance 
may be altered and cause a respiratory acidosis state in the body (Levitzky, 2013). Other effects 
of opioids on the pulmonary system include increased stiffness of the chest wall and lowered 
patency in the upper airway (Yaksh & Wallace, 2011). 
There is no exact definition of respiratory depression that may be used for all patients. 
Determination of respiratory depression must be based on evaluation compared with the patient’s 
baseline. (Pasero & McCaffery, 2011). The relative definition of respiratory depression is part of 
what makes this such a dangerous adverse effect. In order to correctly identify a patient as 
experiencing respiratory depression the health care provider must know the patient’s baseline 
respiratory status.  Thorough respiratory assessment and comparison with the patient’s baseline 
status must be performed to find if the patient is experiencing respiratory depression. 
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2.6 GENETIC INFLUENCE 
Advances in genetics have had major influence on patient care in many different healthcare 
specialties. In the context of opioid pain management, genetic variation may explain differences 
in analgesic and adverse effects in individual patients. These differences in the way that opioids 
exert effects may produce changes in an individual’s risk for opioid induced respiratory 
depression. If the way in which genetics causes changes in an individual's risk for respiratory 
depression can be identified, genetic testing could be used to assess patient risk for opioid 
induced respiratory depression. The candidate genes examined in this study were OPRM1, 
COMT, ABCB1, and CYP2D6.  
 OPRM1 is a gene that will be analyzed in the subjects in this analysis for association 
between a specific genotype and risk for respiratory depression. The gene OPRM1 encodes for 
the mu opioid receptor, where endogenous opioids and opioid analgesics bind (Romberg et al., 
2005). Variation in the mu-receptor has the potential to cause variation in the way that opioid 
binds in the body. Differences in the way that an opioid binds to the mu-receptors may cause 
potential differences in the effects of opioid medication in the body. This variation of the 
behavior of opioids in the body secondary to differences in the mu-receptor has the potential to 
effect an individual’s risk of opioid induced respiratory depression. The fact that the OPRM1 
gene codes for the mu-receptor means that differences in genotype at the OPRM1 gene can cause 
variation in the mu-receptor. This function of the OPRM1 gene creates interest for potential 
differences in risk of opioid induced respiratory depression associated with individual 
differences in the OPRM1 gene. Individual variations in OPRM1 genotype may have 
implications for associated risk for opioid induced respiratory depression.  It has been noted that 
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individual variations in OPRM1 genotype and associated respiratory risk secondary to opioids 
and analgesic effects do not correlate (Romberg et al., 2005). 
 The COMT gene codes for the production of an enzyme called catechol-O-
methyltransferase (U.S. National Library of Medicine, 2007). The function of the enzyme 
catechol-O-methyltransferase in the body is to break down chemical messenger substances called 
neurotransmitters (U.S. National Library of Medicine, 2007). The brain plays an integral role in 
respiratory function. Individual variation in the COMT gene will lead to variation in individuals’ 
catechol-O-methyltransferase enzymes. Differences in individuals’ catechol-O-methyltransferase 
enzymes has the potential to alter the regulation of neurotransmitters in the brain. The alteration 
of neurotransmitters has the potential to affect respiratory function, as well as the behavior of 
opioid medications in the body. These potential differences in respiratory function and effects of 
opioid medications may affect risk for opioid induced respiratory depression. The gene COMT 
has been associated with differences in postoperative pain and response to opioids (Henker et al., 
2013). One of the single nucleotide polymorphisms (SNPs) on the COMT gene analyzed in this 
study was rs4680. This rs4680 SNP on the COMT gene has been associated with a greater opioid 
dose requirement in cancer patients (Rakvag et al., 2008; Reyes-Gibb et al., 2007). These 
differences in opioid response and consumption associated with the COMT gene have a potential 
effect for risk of opioid induced respiratory depression.  
 The function of the ABCB1 gene is to code for the formation of a membrane-associated 
protein that belongs to the MDR/TAP subfamily of membrane transport proteins (U.S. National 
Library of Medicine, 2014). This protein serves a role in the transport of drugs efflux out of cells 
(U.S. National Library of Medicine, 2014). The function of the ABCB1 gene creates interest for 
the potential effect of differences in ABCB1 genotype on an individual’s risk for opioid induced 
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respiratory depression. The function of the membrane-associated protein from the MDR/TAP 
subfamily of membrane transport proteins is to facilitate the efflux of drugs out the cell (U.S. 
National Library of Medicine, 2014). Variation in this membrane-associated protein may 
potentially change the effects of opioid in the body. Due to the function of the ABCB1 gene in 
coding for this membrane-associated protein, differences in the ABCB1 gene may impact risk for 
opioid induced respiratory depression. Differences in an individual's genotype on the ABCB1 
gene have been identified by Park and colleagues (2007) as a risk factor for respiratory 
depression secondary to opioid pain management (Park et al., 2007).   
One of the genes that influence the metabolism of opioid in the body is CYP2D6. The gene 
CYP2D6 encodes for the enzyme that affects the way that a variety of opioids and antiemetics 
are metabolized (Wesmiller et al., 2013). Individual variations in the CYP2D6 gene account for 
differences in metabolism and resulting contrasts in the noticeable effects that the opioids 
produce (Wesmiller et al., 2013). The CYP2D6 gene codes for a monooxygenase protein which 
resides in the endoplasmic reticulum (U.S. National Library of Medicine, 2014). This protein 
belongs to the cytochrome P450 family of enzymes which are known to aid in the metabolism of 
over 20% of drugs (U.S. National Library of Medicine, 2014).  Over 100 different allelic variants 
of the CYP2D6 gene are known to exist in the population (Ingelman-Sundberg, Daly, & Nebert, 
2009). In efforts to simplify the study of these various types of allelic polymorphisms, a 
classification system has been developed describing metabolic function yielded from these 
genetic differences. Based on genotype patients can be classified as poor metabolizers (PM), 
intermediate metabolizers (IM), extensive metabolizers (EM), and ultrarapid metabolizers (UM), 
(Daly et al., 1996; Lotsch et al., 2002; Oertel, Schmidt, Schneider, Geisslinger, & Lotsch, 2006; 
Park et al., 2007; Wesmiller et al., 2013). These differences in an individual’s drug metabolism 
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have the potential to impact opioid metabolism and risk for development of opioid induced 
respiratory depression.  
 
2.7 CLINICAL GUIDELINES 
Evidence based clinical protocols available for determining patients at increased risk for 
opioid induced respiratory depression are limited. Despite this lack of evidence the importance of 
monitoring for both sedation and respiratory depression during opioid medication treatment has 
been noted (Henker & Dunwoody, 2011; Jarzyna et al., 2011; Pasero & McCaffery, 2011). The 
American Society of Pain Management Nursing determined a set of factors as putting individuals 
at increased risk for opioid induced respiratory depression (Jarzyna et al., 2011). The priority risk 
factors found were age above 55 years, obesity (BMI greater than 30), untreated obstructive 
sleep apnea, history of snoring or witnessed apneas, excessive daytime sleepiness, retrognathia 
(teeth misalignment which leads to posterior positioning of the maxilla or mandible), neck 
circumference greater than 17.5 inches, preexisting pulmonary or cardiac disease, major organ 
failure, smoker, ASA Physical Status 3-5, and increased opioid dose requirement (Jarzyna et al., 
2011).  
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3.0  CHAPTER 3: METHODS 
3.1 DESIGN 
A secondary data analysis from a prospective comparative study that explored the differences in 
genotype for the mu opioid receptor, OPRM1 (The association between mu-receptor genotypes 
and postoperative pain response, American Association of Nurse Anesthetists Foundation, Dr. 
Richard Henker) was performed. Data collection was performed by investigators with clinical 
privileges at Presbyterian Hospital of University of Pittsburgh Medical Center. Specific 
information that was collected from the participating subjects included; age, sex, height, weight, 
body mass index, smoking status, race, sedation score postoperatively, amount of opioid received 
in the operating room, amount of opioid received in the PACU, ASA Physical Status and genetic 
risk factors including genetic variants on candidate genes, specifically OPRM1, ABCB1, COMT, 
and CYP2D6. An 11 point verbal pain score was used to evaluate subjects’ pain response. 
Subjects were taught how to use the scale to communicate pain score prior to surgery to aid in 
increasing the accuracy of patients’ use of the scale post operatively. To obtain subjects genetic 
information, saliva samples for DNA extraction were collected in the clinical unit after the 
patient had left the PACU. Saliva samples were preserved in Oragene DNA self collection kit 
from DNA Genotek corporation (Ottawa, ON, Canada). The amount of opioid that subjects 
received was measured in the operating room and 45 minutes following surgery, while the 
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subject was in the PACU. Information regarding specific opioid medication administered, 
amount administered, and time of administration for each subject was gathered from the PACU 
and perioperative records. Respiratory rates at 15 minutes and 45 minutes postoperatively were 
collected from the subjects’ medical records. 
3.2 SAMPLE 
 A sample of 152 adult subjects that received surgery for orthopedic trauma were used for 
analysis of differences in genotype for the mu opioid receptor, OPRM1 (The association between 
mu-receptor genotypes and postoperative pain response, American Association of Nurse 
Anesthetists Foundation, Dr. Richard Henker) in the parent study. In this secondary analysis 152 
of the subjects from the original sample from the parent study were included for analysis of risk 
factors for opioid induced respiratory depression. Due to missing data, 8 subjects from the 
original sample from the parent study were not included in this secondary analysis.  
Inclusion criteria were: diagnosis of single isolated extremity fracture, and age between 18-70 
years. Exclusion criteria included: opioid consumption within the past 6 months (not including 
the current hospital admission), history of alcohol abuse, alcohol use within the 
last 24 hours (3 drinks or greater), history of mental illness, current use of phenothiazines, 
history of hepatic disease, history of renal disease, history of neurological trauma, and having an 
American Society of Anesthesiologists Physical Status rating greater than 3 (American Society 
of Anesthesiologists, 2014). 
 Orthopedic trauma patients undergoing surgical repair were chosen for this study due to 
the reports of high pain levels reported with these types of injuries. The high pain levels that 
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these patients experience require rigorous and comprehensive pain management, for which the 
gold standard of treatment includes opioids. The high frequency of opioid pain control used in 
this population provided ample data for analysis of risk factors for opioid induced respiratory 
depression. In the parent study a sample of opioid naive subjects was chosen intentionally to 
limit the influence that opioid tolerance has on opioid pain control. Opioid tolerance goes hand in 
hand with changes in opioid receptors that alters the course of opioid pain control as compared to 
opioid naive subjects. An opioid naive population was chosen with the intention of minimizing 
threats to internal validity of the study. Single isolated extremity fracture was the specific 
orthopedic trauma diagnosis included in this sample, due to the variation of ages that present 
with this type of injury. Inclusion of a wide range of ages is preferred to limit influence on 
results from the unique characteristics of any one specific age group. Incorporation of a variety 
of ages in the sample aims to minimize threats to external validity of the study. 
3.3 DATA COLLECTION 
3.3.1 Recruitment 
Subjects were recruited in the preoperative holding area and inpatient units at Presbyterian 
hospital of University of Pittsburgh Medical Center. Data from patient reports and medical 
records were gathered to ensure that the subject met the selection criteria for the study. Subject 
demographics, co-morbidities, physical status, laboratory values, preoperative and intraoperative 
medications were all evaluated. The subject was enrolled in the study only if criteria for 
participation were met and informed consent was obtained. 
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3.3.2 Anesthesia Management 
Intraoperative anesthesia management included: Midazolam <4 mg; Propofol 
(<3mg/kg) or Sodium thiopental 4-6mg/kg; Succinylcholine or Rocuronium; Fentanyl; 
hydromorphone; vasoactive medications as needed; and inhaled agents such as isoflurane, 
sevoflurane, or desflurane. Amount of phenylephrine administered did not exceed 400 mcg. 
Dose of ephedrine administered did not exceed 25 mg during surgery. 
3.3.3 Pain Scale 
Pain was measured in the PACU at 15 minutes and 45 minutes postoperatively utilizing the 11-
point verbal pain response scale. Education regarding how to use the 11-point verbal pain 
response scale was provided to patients prior to surgery. Utilizing the verbal pain response scale 
patients were asked to rate their pain from 0 (no pain) to 10 (the worst pain imaginable). 
3.3.4 Opioids 
All opioid medications that subjects received were collected from the perioperative and PACU 
medical records. Medication type, dosage, and time of administration were all collected. 
Fentanyl was recorded both separately as well as included in total opioids. Dosage of fentanyl 
was reported in mcg/kg. In efforts to analyze fentanyl in the context of standardized opioid 
amount, dosage of fentanyl was converted to mg of morphine equivalents, and divided by kg of 
body weight. 
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3.3.5 Demographic Information 
Age, sex, height, weight, body mass index, smoking status, and race were all obtained from both 
the medical record and patient report. Race/ethnicity categories used are the following as defined 
by the NIH; Caucasian, Black or African-American, Asian or Pacific Islander, Hispanic, and 
Native American (Office of Management and Budget, 1997). ASA (American Society of 
Anesthesiologists) Physical Classification is an additional aspect of subject demographic data 
that was collected. The ASA Physical Classification categorizes patients according to level of 
acuity on a 1-6 scale; 1 is a normal healthy patient, 2 is a patient with mild systemic disease, 3 is 
a patient with severe systemic disease, 4 is a patient with severe systemic disease that is a 
constant threat to life, 5 is a moribund patient who is not expected to survive without the 
operation, and 6 is a declared brain-dead patient whose organs are being removed for donor 
purposes (ASA, 2014). If the case is deemed emergent, an E is used to denote the emergency 
nature of the case. (ASA, 2014). The subjects’ health history of comorbidities including diabetes 
mellitus, hypertension, cardiac heart failure, myocardial infarction, and chronic obstructive 
pulmonary disease, past surgical history, and alcohol use were gathered from both the medical 
record and patient report. 
3.3.6 Saliva Samples 
The Oragene self-collection kit from DNA Genotek corporation (Ottawa, ON, Canada) was used 
for collection of subject saliva samples for DNA extraction. Vials used for collection of saliva 
contained a stabilization buffer with which the saliva mixed when added to the vial. The mixture 
of saliva and stabilization buffer in the vials was stable at room temperature for extended periods 
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of time. Dr. Yvette Conley’s lab extracted DNA from the saliva samples using protocol and 
reagents included with the Oragene self-collection kit. The quantity of DNA extracted from each 
saliva sample was approximately 100ug. This amount of DNA was more than required for the 
genotypic analysis used in this study. 
3.3.7 Genotype Data 
The candidate genes that were genotyped and analyzed for this study were; OPRM1, variants 
A118G (rs1799971), and C17T (rs1799972), COMT SNPs; (rs6269), (rs4633), (rs4818), and 
(rs4680), ABCB1 SNPs; (rs1045642), (rs2032582), (rs1128503), (rs1202168), and (rs3213619) 
and CYP2D6 metabolizer groups. The A118G polymorphism of OPRM1 at position 118 has the 
AA genotype which is the homozygous wild type while the AG, and GG genotypes are the 
genetic variants. The C17T polymorphism of OPRM1 at position 17 has the CC genotype which 
is homozygous wild type, while CC and CT at this position are the genetic variant genotypes. 
The SNP (rs6269) of the COMT gene has the AA genotype which is the homozygous wild type 
while the AG, and GG genotypes are the genetic variants. The SNP (rs4633) of the COMT gene 
has the CC genotype which is the homozygous wild type while the CT, and TT genotypes are the 
genetic variants. The SNP (rs4818) of the COMT gene has the CC genotype which is the 
homozygous wild type while the CG, and GG genotypes are the genetic variants. The SNP 
(rs4680) of the COMT gene has the GG genotype which is the homozygous wild type while the 
GA, and AA genotypes are the genetic variants. The ABCB1 gene SNP (rs1045642) has the GG 
genotype which is the homozygous wild type while the GA, and AA genotypes are the genetic 
variants. The ABCB1 gene SNP (rs2032582) has the CC genotype which is the homozygous wild 
type while the CT, and TT genotypes are the genetic variants. The ABCB1 gene SNP 
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(rs1128503) has the GG genotype which is the homozygous wild type while the GA, and AA 
genotypes are the genetic variants. The ABCB1 gene SNP (rs1202168) has the GG genotype 
which is the homozygous wild type while the GA, and AA genotypes are the genetic variants. 
The ABCB1 gene SNP (rs3213619) has the AA genotype which is the homozygous wild type 
while the AG, and GG genotypes are the genetic variants. Subjects were classified into CYP2D6 
metabolizer groups according to genotype (Wesmiller et al., 2013).  
One sequencing reaction was needed to identify the subjects’ genotypes at A118G and 
C17T due to the fact that these are within 101 base pairs of each other on exon 1. Primers were 
designed to flank the genetic variants, which were then amplified using polymerase chain 
reaction (PCR). The PCR fragments were cleaned using exoSAP reagents (US Biochemicals, 
Cleveland, OH). Sequencing was performed using Big Dye Cycle Sequencing reagents (Applied 
Biosystems Inc, Foster City, CA). The resulting data was converted into viewable data and 
assigned genotypes using Sequencer software (Gene Codes Corporation, Ann Arbor, MI).  
TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster City, CA) was used 
to genotype the COMT, ABCB1, and CYP2D6 genes. The subjects’ single nucleotide 
polymorphisms were determined utilizing 5’ exonuclease Assay on Demand TaqMan assays 
(ABI). The genetic variants were flanked with the use of primers. Fluorescent oligonucleotide 
probes in a homogeneous assay were used to amplify the fragments using PCR. Genetic variants 
were amplified and identified using ABI Prism7000 sequence detection system and SDS 2.0 
software. All genotype data were stored in a secure data file on SPSS (SPSS 17.0, Chicago, IL) 
on a password protected computer. 
Before testing for association with phenotypes, all the genetic variants (SNPs) were 
tested for Hardy-Weinberg equilibrium (HWE) using the exact method (Wigginton et al., 2005) 
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implemented in the PLINK software (Purcell et al., 2007). All the SNPs with a HWE p-value of 
less than 0.05 will be flagged for extra attention in explanations of any association findings. To 
investigate the additive, dominant, and recessive genetic effect of variant allele (minor allele) on 
phenotypic variation of our outcome measures, we also recoded raw genotypes of all SNPs into 
three new variables that are consistent to three genetic models. That is, the homozygous major 
allele genotype, heterozygous genotype, and homozygous variant (minor) allele genotype will be 
coded as 0, 1, and 2 under additive model, coded as 0, 1, 1, under dominant model, coded as 0, 0, 
1 under recessive model, respectively. 
3.3.8 Data Cleaning 
Data were stored and analyzed utilizing the program SPSS. Categorical variables were assigned a 
number code in SPSS for organizational and analysis purposes. For variables of interest in which 
data was unavailable during prospective data collection, the data was collected retrospectively. 
Data was reviewed and re-checked frequently to ensure that the data was entered correctly into 
SPSS from the subjects’ medical records. 
3.4 ANALYSIS 
Descriptive statistics were used to determine the minimum, maximum, range, mean and standard 
deviation of all continuous variables. Frequencies were computed for all categorical variables.  
Univariate analyses were first performed to assess association of non-genetic risk factors with 
outcomes (i.e., respiratory rate at 15 and 45 minutes, and change in respiratory rate between 15 
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and 45 min, respectively). For continuous risk factors, simple linear regression method was used. 
For categorical risk factors, one-way analysis of variance (ANOVA) method was used to 
compare the mean difference of outcome between or among each category. 
Single-marker genetic association analysis was then performed by multiple linear 
regression analyses of each outcome that modeled the specific genetic inheritance model 
(additive, dominant, recessive) of each SNP, after adjusting for these non-genetic variables 
which are at least marginally significant at p<0.20 in univariate analyses. Bonferroni correction 
method will be applied to adjust from multiple comparisons. A P-value of less than 0.05 will be 
considered to statistically significant. All statistical analyses were performed using the software 
SPSS (SPSS 17.0, Chicago, IL). 
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4.0  CHAPTER 4: RESULTS 
4.1 SUBJECT CHARACTERISTICS 
Descriptive statistics were used to summarize subject characteristics that were continuous 
variables (See Table 1). The sample consisted of a total of 152 subjects ranging from age 18-70. 
The average height of subjects was 173.01 cm with a standard deviation of 18.25, ranging from 
64 cm to 206cm. The average weight of the sample was 89.13kg with a standard deviation of 
20.81, ranging from 48 kg to 170 kg. Body mass index of the sample ranged from 18.42 to 69.86 
with an average of 29.04 and standard deviation of 7.38. Amount of opioid received in the 
operating room ranged from 0 mg to 103.33 mg with an average of 34.81 mg and standard 
deviation of in 18.07 mg of Morphine equivalents. The amount of opioid that subjects consumed 
in the operating room by weight ranged from 0 mg/kg to 1.35 mg/kg with an average of 0.40 
mg/kg and standard deviation of 0.22. The amount of opioid consumed in the PACU within the 
first 45 minutes postoperatively ranged from 0mg to 31.33mg with an average of 7.77mg and 
standard deviation of 6.02. The amount of opioid consumed by weight in the PACU within the 
first 45 minutes postoperatively ranged from 0mg/kg to 0.37 mg/kg with an average of 0.09 and 
standard deviation of 0.07. Frequencies were used to summarize subject characteristics that were 
categorical variables (See Table 2). American Society of Anesthesiologists (ASA) physical status 
of the subjects was as follows; 30 subjects had an ASA physical status of 1, 87 subjects had an 
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ASA physical status of 2, and 17 subjects had an ASA physical status of 3. There were 104 
males and 48 females in the sample. There were 65 subjects that were smokers and 86 that were 
nonsmokers. Smoking status data was unavailable for 1 subject. The racial makeup of the sample 
was as follows, there were 121 White subjects, 24 African American subjects, 4 Asian subjects, 
2 Hispanic subjects, and 1 American Indian subject. American Society of Anesthesiologists 
(ASA) Physical Status Classifications of the sample are as follows; 30 subjects had an ASA 
classification of 1, 87 subjects had an ASA classification of 2, 17 subjects had an ASA 
classification of 3, and data regarding ASA classification was unavailable for 18 of the subjects. 
Subject sedation score was reported in frequencies (See Table 3). At 15 minutes postoperatively; 
38 subjects had a sedation score of 0, 79 subjects had a sedation score of 1, 10 subjects had a 
sedation score of 2, 0 subjects had a sedation score 3, 2 subjects had a sedation score of 4, and 1 
subject had a sedation score of 5. At 45 minutes postoperatively; 58 subjects had a sedation score 
of 0, 58 subjects had a sedation score of 1, 3 subjects had a sedation score of 2, 0 subjects had a 
sedation score of 3, 9 subjects had a sedation score of 4, and 0 subjects had a sedation score of 5.  
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Table 1. Subject Characteristics, Descriptive Statistics. 
Subject Characteristic N Data 
Unavailable 
Range Minimum Maximum Mean Std. 
Deviation 
Age 152 0 52 18 70 38.48 13.13 
Height (cm) 149 3 142 64 206 173.01 18.25 
Weight (kg) 152 0 122 48 170 89.13 20.81 
BMI 149 3 51.44 18.42 69.86 29.04 7.38 
OR Opioid Administered in mg of 
Morphine equivalents 
151 1 103.33 .00 103.33 34.81 18.07 
OR Opioid Administered by 
weight (kg) 
151 1 1.35 .00 1.35 .40 .22 
Opioid Administered in the 
PACU within 45 minutes 
148 4 31.33 .00 31.33 7.77 6.02 
Opioid Administered in the 
PACU within 45 minutes by 
weight 
148 4 .37 .00 .37 .09 .07 
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Table 2. Frequencies of Subject Characteristics 
Subject 
Characteristic 
Characteristic 
Subcategory 
Frequency Percent 
Gender Male 104 68.4% 
 Female 48 31.6% 
 Unavailable 0 - 
 Total 152 100% 
Smoking Status Non Smoker 86 57% 
 Smoker 65 43% 
 Unavailable 1 - 
 Total 151 100% 
Race White (non-Hispanic) 121 79.6% 
 African-American 24 15.8% 
 Asian 4 2.6% 
 Hispanic 2 1.3% 
 American Indian 1 .7% 
 Unavailable 0 - 
 Total 152 100% 
ASA Physical 
Status 
1 30 22.4% 
 2 87 64.9% 
 3 17 12.7% 
 Unavailable 18 - 
 Total 134 100% 
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Table 3. Frequencies of Subject Sedation Score 
Sedation Score at 15 
minutes 
postoperatively 
Frequency Percent 
0 38 29.2% 
1 79 60.8% 
2 10 7.7% 
3 0 0% 
4 2 1.5% 
5 1 0.8% 
Unavailable 22 - 
Total 152 100% 
Sedation Score at 45 
minutes 
postoperatively 
Frequency Percent 
0 58 37.9% 
1 58 37.9% 
2 3 2.0% 
3 0 0% 
4 9 5.9% 
5 0 0% 
Unavailable 24 - 
Total 152 100% 
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4.2 SUBJECT GENETIC CHARACTERISTICS 
The genes studied were OPRM1, COMT, ABCB1, and CYP2D6. Subject characteristics 
regarding the genes OPRM1, COMT, and ABCB1 are summarized (See Table 4). The A118G 
SNP on the gene OPRM1 was analyzed in sample by separating individuals by genotype; 106 
subjects had the genotype AA, 28 subjects had the genotype AG, and 2 subjects had the genotype 
GG. The SNP C117T on the gene OPRM1 was also studied; 132 subjects had the genotype CC, 5 
subjects had the genotype CT, and 1 subject had the genotype TT. For the COMT (rs4680) SNP, 
26 subjects had the genotype AA, 39 had the genotype GG, and 32 had the genotype AG.  For 
the COMT (rs6269) SNP, 31 subjects had the AA genotype which is the homozygous wild type 
while 38 subjects had the AG genotype and 22 subjects had the GG genotype. For the COMT 
(rs4633) SNP, 38 subjects had the CC genotype which is the homozygous wild type while 31 
subjects had the CT genotype and 26 subjects had the TT genotype. For the COMT (rs4818) 
SNP, 37 subjects had the CC genotype which is the homozygous wild type while 37 subjects had 
the CG genotype and 22 subjects had the GG genotype. For the COMT (rs4680) SNP 39 subjects 
had the GG genotype which is the homozygous wild type while 32 subjects had the GA genotype 
and 26 subjects had the AA genotype. For the ABCB1 gene SNP (rs1045642), 39 subjects had 
the GG genotype which is the homozygous wild type while 51 subjects had the GA genotype and 
19 subjects had the AA genotype. For the ABCB1 gene SNP (rs2032582) 90 subjects had the CC 
genotype which is the homozygous wild type while 3 subjects had the CT genotype and 5 
subjects had the TT genotype. For the ABCB1 gene SNP (rs1128503), 48 subjects had the GG 
genotype which is the homozygous wild type while 49 subjects had the GA genotype and 11 
subjects had the AA genotype. For the ABCB1 gene SNP (rs1202168), 41 subjects had the GG 
genotype which is the homozygous wild type while 48 subjects had the GA genotype and 10 
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subjects had the AA genotype. For the ABCB1 gene SNP (rs3213619), 99 subjects had the AA 
genotype which is the homozygous wild type while 10 subjects had the AG genotype and 1 
subject had the GG genotype. Subjects were classified into CYP2D6 metabolizer groups 
according to genotype (Wesmiller et al., 2013).  
  Subjects were separated by CYP2D6 metabolizer groups for analysis (See Table 5); 7 
subjects were poor metabolizers, 54 subjects were intermediate metabolizers, 79 subjects were 
extensive metabolizers, and 0 subjects were ultrarapid metabolizers. 
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Table 4. Summary Information of COMT, ABCB1, OPRM1 SNPs 
 
 
 
 
 
 
 
 
Allelesa  
 
 
 
Genotype  
 
 
 
 
 
Gene SNP Chr Position A1 A2 MAFb A1/A1 A1/A2 A2/A2 HWEc 
COMT rs6269 22 19949952 G A 0.4505 22 38 31 0.141 
 
 
rs4633 22 19950235 T C 0.4368 26 31 38 0.0015 
 
 
rs4818 22 19951207 G C 0.4219 22 37 37 0.0388 
 
 
rs4680 22 19951271 A G 0.433 26 32 39 0.0017 
ABCB1 rs1045642 7 87138645 A G 0.4083 19 51 39 0.8426 
 
 
rs2032582 7 87160618 T C 0.0663 5 3 90 1.05E-06 
 
 
rs1128503 7 87179601 A G 0.3287 11 49 48 1 
 
 
rs1202168 7 87195962 A G 0.3434 10 48 41 0.5122 
 
 
rs3213619 7 87230193 G A 0.0546 1 10 99 0.2715 
OPRM1 rs1799972 (C17T) 6 154360696 T C 0.0254 1 5 132 0.0750 
 
 
rs1799971 (A118G) 6 154360797 G A 0.1176 2 28 106 1 
a: A1: Minor or Variant allele; A2: Major or wide-type allele.       
b: MAF: Minor allelic frequency.       
c: Hardy-Weinberg Equilibrium (HWE) test P-value. 
(Note: observed heterozygotes less than expected numbers, causing HWE p < 0.05) 
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Table 5. Summary Information of CYP2D6 Metabolizer Groups 
 
 
Frequency Percent 
PM (Poor Metabolizers) 7 5.0% 
IM (Intermediate Metabolizers) 54 38.6% 
EM (Extensive Metabolizers) 79 56.4% 
UM (Ultrarapid Metabolizers) 0 - 
Data Unavailable 12 - 
Total 140 100.0 
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4.3 SUBJECT DEMOGRAPHICS AND RESPIRATORY RATE AT 15 AND 45 
MINUTES POSTOPERATIVELY 
The subject characteristics age, sex, race, height, weight, BMI, amount of opioid received in the 
operating room, amount of opioid received in the PACU and smoking status were not found to 
have a significant influence on respiratory rate at 15 or 45 minutes post operatively (See Table 
6). Sedation scores at 15 and 45 minutes were found to have a significant association with 
respiratory rate at 15 and 45 minutes postoperatively (See Tables 6 and 7). ASA physical status 
was found to have a significant influence on respiratory rate (See Table 6). A higher ASA 
physical status was associated with higher respiratory rate at both 15 and 45 minutes 
postoperatively (See Table 8). Post Hoc analysis revealed significant difference between ASA 
Physical Status groups 1 and 3, and 2 and 3 for respiratory rate at 15 minutes postoperatively. At 
45 minutes postoperatively Post Hoc analysis revealed significant difference in respiratory rate 
between ASA Physical Status Groups 1 and 3.  
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 Table 6. Subject Demographics Analysis P-values 
  Postoperative 
Respiratory Rate 
15 minutes after 
admission to the 
PACU 
Respiratory 
Rate 45 
minutes after 
admission to 
the PACU 
Change in 
RR Between 
15 and 45 
min 
Age  0.75  0.85 0 .65 
Height 0.72 0.76 0.94 
Weight 0.59 0.38 0.24 
BMI 0.98 0.99 0.91 
OR Opioid 
in mg of 
Morphine 
equivalents 
0.64 0.52 0.90 
OR Opioid 
by Weight 0.69 0.65 0.97 
Sex 0.65 0.99 0.77 
Race 0.09 0.19 0.65 
ASA 
Physical 
Status 
0.01 0.01 0.95 
Smoking 
Status 0.12 0.90 0.28 
Presby 
Sedation 
Score at 15 
minutes 
0.05 0.01 0.45 
Presby 
Sedation 
Score at 45 
minutes 
0.008 0.004 0.11 
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Table 7. Subjects’ Average Respiratory Rate by Sedation Score 
Sedation Score at 
15 minutes 
postoperatively 
Frequency Percent Respiratory Rate at 15 minutes 
postoperatively,  
Mean (Standard Deviation) 
Respiratory Rate at 45 
minutes postoperatively, 
Mean (Standard Deviation) 
0 38 29.2% 16.55 (3.94) 16.58 (4.73) 
1 79 60.8% 15.05 (4.45) 14.59 (3.94) 
2 10 7.7% 15.30 (3.97) 12.56 (1.33) 
3 0 0% - - 
4 2 1.5% 20.50 (2.12) 20.00 (9.89) 
5 1 0.8% 24.00 (-) 20.00(-) 
Unavailable 22 - - - 
Total 152 100% 15.67 (4.35) 15.16 (4.32) 
Sedation Score at 
45 minutes 
postoperatively 
Frequency Percent Respiratory Rate at 15 minutes 
postoperatively, 
Mean(Standard Deviation) 
Respiratory Rate at 45 
minutes postoperatively, 
Mean(Standard Deviation) 
0 58 37.9% 15.78 (3.93) 16.14 (4.49) 
1 58 37.9% 14.61 (4.27) 13.86 (3.24)   
2 3 2.0% 14.00 (3.61) 12.00 (-) 
3 0 0% - - 
4 9 5.9% 21.44 (3.75) 17.89 (6.47) 
5 0 0% - - 
Unavailable 24 - - - 
Total 152 100% 15.61 (4.37) 15.17 (4.30) 
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 Table 8. Subjects’ Average Respiratory Rate by ASA Physical Status 
ASA 
Physical 
Status 
Frequency Percent Respiratory Rate at 15 
minutes postoperatively, 
Mean(Standard Deviation) 
Respiratory Rate at 45 
minutes postoperatively, 
Mean(Standard Deviation) 
1 30 22.4% 14.70 (2.89) 14.00 (3.20) 
2 87 64.9% 15.53 (3.97) 15.22 (4.37) 
3 17 12.7% 18.47 (5.41) 17.82 (4.23) 
Unavailable 18 - - - 
Total 152 100% 15.72 (4.10) 15.28 (4.23) 
 
 
 
 
 
 
 
 
 
 37 
4.4 GENETIC CHARACTERISTICS AND RESPIRATORY RATE AT 15 AND 45 
MINUTES POSTOPERATIVELY 
Variation in the subject’s genotype on genes OPRM1 and COMT was not found to have an 
association with respiratory rate at 15 or 45 minutes post operatively (See Table 9). Differences 
in subject genotype on the ABCB1 gene for the SNP (rs1045642) were associated with variation 
in respiratory rate at 45 minutes postoperatively (See Tables 9 and 10). CYP2D6 metabolizer 
group classification was associated with differences in respiratory rate at 15 minutes 
postoperatively (See Tables 11 and 12). Post Hoc analysis revealed significant difference among 
CYP2D6 metabolizer groups in respiratory rate between poor metabolizers versus intermediate 
metabolizers and poor metabolizers versus extensive metabolizers at 15 minutes postoperatively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 Table 9. Genetic Association Analysis P-values 
Gene SNP 
Postoperative 
Respiratory 
Rate 15 
minutes after 
admission to 
the PACU 
Respiratory 
Rate 45 
minutes after 
admission to 
the PACU 
Change in RR 
Between 15 and 
45 min 
COMT rs6269 0.52 0.10 0.20 
  rs4633 0.16 0.65 0.48 
  rs4818 0.62 0.13 0.20 
  rs4680 0.28 0.74 0.57 
ABCB1 rs1045642 0.19 0.02 0.40 
  rs2032582 0.32 0.78 0.58 
  rs1128503 0.42 0.91 0.66 
  rs1202168 0.28 0.72 0.66 
  rs3213619 0.94 0.65 0.61 
OPRM1 rs1799972 (C17T) 0.49 0.36 0.72 
  rs1799971 
(A118G) 0.39 0.94 0.50 
  
 
 
Table 10. Subjects’ Average Respiratory Rate by ABCB1 SNP (rs1045642) genotype 
ABCB1 
Genotype, 
SNP 
(rs1045642) 
Frequency Percent Respiratory Rate at 15 
minutes postoperatively, 
Mean (Standard Deviation) 
Respiratory Rate at 45 
minutes postoperatively, 
Mean(Standard Deviation) 
GG 39 25.7% 16.51 (3.91) 14.23 (3.62) 
GA 51 33.6% 15.35 (4.39) 16.08 (4.30) 
AA 19 12.5% 15.67 (4.33) 16.65 (6.04) 
Unavailable 43 - - - 
Total 152 100% 15.82 (4.21) 15.50 (4.46) 
 
 39 
 Table 11. CYP2D6 Analysis P-values 
CYP2D6, Metabolizer 
Groups 
Postoperative Respiratory 
Rate 15 minutes after 
admission to the PACU 
Respiratory Rate 45 
minutes after admission to 
the PACU 
Change in RR Between 
15 and 45 min 
P-value 0.001 0.06 0.37 
 
 
Table 12. Subject’s Average Respiratory Rate by CYP2D6 Metabolizer Group 
CYP2D6 Metabolizer Group 
 
Frequency Percent Respiratory Rate at 15 
minutes postoperatively, 
Mean(Standard Deviation) 
Respiratory Rate at 45 
minutes postoperatively, 
Mean(Standard Deviation) 
PM (Poor Metabolizers) 7 5.0% 11.00 (2.45) 13.00 (2.71) 
IM (Intermediate Metabolizers) 54 38.6% 15.24 (2.91) 14.44 (3.99) 
EM (Extensive Metabolizers) 79 56.4% 16.50 (4.56) 15.95 (4.45) 
UM (Ultrarapid Metabolizers) 0 0% - - 
Data Unavailable 12 - - - 
Total 152 100.0 15.72 (4.09) 15.21 (4.27) 
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5.0  DISSCUSSION 
This study found that American Society of Anesthesiologists (ASA) physical status classification 
and differences in CYP2D6 metabolizer groups were associated with differences in respiratory 
rate postoperatively. There is limited evidence available regarding the use of ASA physical status 
classification to gauge risk for opioid induced respiratory depression postoperatively (Jarzyna et 
al., 2011). Despite the lack of evidence available regarding the use of ASA physical status to 
determine risk for postoperative opioid induced respiratory depression specify, there are studies 
demonstrating the efficacy of ASA physical status as a means of predicting operative risk 
(Albarran, Simoens, van de Winkel, da Costa, & Thill, 2009; Brouquet, Cudennec, Benoist, 
Moulias, Beauchet, et al., 2010; Chida, Ono, Hoshikawa, & Kondo, 2008; Johnson et al., 2007; 
Peersman, Laskin, Davis, Peterson, & Richart, 2008; Sanjay, Jones, & Woodward, 2006; Skaga, 
Eken, Sovik, Jones, & Steen, 2007; Wolters et al., 1996). These studies demonstrated that ASA 
physical status was associated with a patient’s risk of developing a variety of postoperative 
complications. The findings of this study support the findings of these previous studies 
demonstrating that ASA physical status is associated with increased risk of postoperative 
complications. In the present analysis, ASA physical status was associated with differences in 
respiratory rate at 15 and 45 minutes postoperatively. Although in the present study higher ASA 
Physical Status score was associated with an increased respiratory rate postoperatively.  
 41 
ASA physical status is a classification used in standard practice in the management of 
surgical patients. These findings provide further evidence to support the use of ASA physical 
status to identify individuals at increased risk for postoperative respiratory depression. The 
application of ASA physical status to identify individuals at increased risk for postoperative 
respiratory depression translates readily into clinical practice because of the current widespread 
use of ASA physical status in clinical practice. The correlation of both these factors with 
postoperative respiratory depression have potential applications in clinical practice. With the 
application of genetic testing, patients could be identified by metabolizer group and have drug 
therapy tailored to decrease the risk of postoperative respiratory depression. 
 Available evidence of the role of genetic differences in the CYP2D6 gene and 
development of respiratory depression is predominantly in the form of case studies of pediatric 
patients. In examining the genetic differences between pediatric patients that experienced fatal 
opioid induced respiratory depression postoperatively it was found that genetic differences on the 
CYP2D6 gene were not strongly associated with the risk of opioid induced respiratory depression 
(Racoosin, Roberson, Pacanowski, & Nielsen, 2013). These findings contrast with the findings 
of this analysis which found that differences in CYP2D6 metabolizer group classification were 
associated with differences in respiratory rate postoperatively. One of the possible reasons for the 
difference would be age of the sample.  
It has been noted in the literature that genetic differences on the ABCB1 gene can result in 
differences in an individual’s reaction to opioid medications (Dahan & Kest, 2001; Mercer & 
Coop, 2011; Niesters, Overdyk, Smith, Aarts, & Dahan, 2013; Park et al., 2007). Specifically the 
role of the ABCB1 gene in risk for opioid induced respiratory depression has been evaluated and 
found to be significant (Dahan & Kest, 2001; Mercer & Coop, 2011; Niesters, Overdyk, Smith, 
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Aarts, & Dahan, 2013; Park et al., 2007).  The present study found that difference in subject 
genotype on the ABCB1 gene was associated with differences in respiratory rate 45 minutes 
postoperatively. These findings are in agreement with current available literature on this subject. 
The findings of this study along with the findings of the current literature support the use of 
genetic data regarding the ABCB1 gene to asses an individual’s risk for opioid induced 
respiratory depression.  
The subject characteristics age, sex, height, weight, body mass index, smoking status, 
race, amount of opioid received in the operating room, amount of opioid received in the post 
anesthesia care unit (PACU) and genotype data including: single nucleotide polymorphism 
(SNPs) from the candidate genes of interest OPRM1 and COMT. There is evidence to suggest 
that age over 65 years is associated with opioid induced respiratory depression (Auburn & 
Marmion, 2007; Taylor, Kirton, Staff, & Kozol, 2005).  
One of the limitations of this study is inherent in the secondary analysis design. The data used for 
analysis in this study was originally collected for a prospective comparative study that evaluated 
the differences in genotype for the mu opioid receptor, OPRM1 (The association between mu-
receptor genotypes and postoperative pain response, American Association of Nurse Anesthetists 
Foundation, Dr. Richard Henker). Secondary analysis design presents challenges because the 
data was not collected for the purposes of the current study. An additional limitation to this study 
was the collection of data retrospectively that was unavailable during prospective data collection. 
Retrospective data collection is problematic because of the increased risk of error with this 
method of data collection. One of the other limitations of this study was the sample size. This 
creates difficulty in ruling out other possible influences on the results such as age. In other 
studies (Aubrun & Marmion, 2007; Cepeda et al., 2003) age has been found to be associated 
 43 
with opioid induced respiratory depression. The relatively small size of this sample makes it 
difficult to attain significance in all factors that may be associated with changes in respiratory 
rate. In particular in the CYP2D6 metabolizer groups there were no ultrarapid metabolizers and 7 
poor metabolizers. In analysis of genetic characteristics a larger sample size is preferable.  
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